'Secondary' acute lymphoblastic/lymphocytic leukemia - done playing second fiddle?

Autor: Riazat-Kesh YJRA; Icahn School of Medicine Mount Sinai West and Morningside, 1000 Tenth Avenue, New York, NY 10019, United States of America. Electronic address: yosefjosephrene.amelriazat-kesh@mountsinai.org., Mascarenhas J; Ruttenberg Treatment Center, Tisch Cancer Institute, 1470 Madison Avenue, 3rd Floor, New York, NY, 10029., United States of America. Electronic address: john.mascarenhas@mssm.edu., Bar-Natan M; Ruttenberg Treatment Center, Tisch Cancer Institute, 1470 Madison Avenue, 3rd Floor, New York, NY, 10029., United States of America. Electronic address: michal.bar-natan@mssm.edu.
Jazyk: angličtina
Zdroj: Blood reviews [Blood Rev] 2023 Jul; Vol. 60, pp. 101070. Date of Electronic Publication: 2023 Mar 05.
DOI: 10.1016/j.blre.2023.101070
Abstrakt: Acute lymphoblastic/lymphocytic leukemia (ALL) occurring post-cancer diagnosis (secondary ALL - sALL) is increasingly recognized as a discrete entity, constituting up to as much as 5-10% of all new ALL diagnoses, and carrying its own biologic, prognostic and therapeutic significance. In this review, we will outline the history and current state of research into sALL. We will explore the evidence for differences underlining its existence as a distinct subgroup, as well as examining what might be driving such differences etiologically, including prior chemotherapy. We will examine these distinctions on population-, chromosomal-, and molecular-levels, and we will consider whether they translate to differences in clinical outcome, and whether they do - or should - warrant differences in treatment selection.
Competing Interests: Declaration of Competing Interest None to disclose.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: